CN108310275A - Treat heat symptom-complex urarthritis on behalf of the tea - Google Patents
Treat heat symptom-complex urarthritis on behalf of the tea Download PDFInfo
- Publication number
- CN108310275A CN108310275A CN201810431705.7A CN201810431705A CN108310275A CN 108310275 A CN108310275 A CN 108310275A CN 201810431705 A CN201810431705 A CN 201810431705A CN 108310275 A CN108310275 A CN 108310275A
- Authority
- CN
- China
- Prior art keywords
- group
- urarthritis
- complex
- tea
- significant difference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention, which discloses, a kind for the treatment of heat symptom-complex urarthritis on behalf of the tea, it is characterised in that each component mass ratio is as follows：2 parts of honeysuckle, 2 parts of Radix Angelicae Sinensis, 1 part of Radix Glycyrrhizae, 1 part of pueraria lobata, 1 part of purslane, 1 part of Semen Coicis, 1 part of hoveniae semoveniae semen, 1 part of Poria cocos.Overcome traditional decoction and decoct the shortcomings of cumbersome, inconvenient to carry, can several times of drinking at any time for a long time, slowly recuperate under medical treatment, can not only alleviate heat symptom-complex but also can effectively treat urarthritis, and the recurrent exerbation of avoidable urarthritis.
Description
Technical field
The present invention relates to one kind on behalf of the tea, especially a kind of to treat heat symptom-complex urarthritis on behalf of the tea.
Background technology
As living and diet level improves, dietary structure variation causes human body health hidden danger occur.Hyperuricemia and
Patient with gout incidence is in apparent ascendant trend, and general population's prevalence of gout about 1 ~ 3%, male to female ratio is about 15：1, average year
Age is 48.28 years old.Clinically, urarthritis is treated using non-steroid anti-inflammatory drug and glucocorticoid etc., Chang Yin
Play the side effects such as gastrointestinal toxicity, dependence, liver and bone marrow toxicity, allergy and Toxicity of Kidney.To avoid Western medicine from causing
Side effect, existing traditional Chinese medicine is applied to the treatment of urarthritis at present, but offer limited effectiveness.Chinese medicine is to use on behalf of the tea
The Chinese medicine of medicine-food two-purpose or with tealeaves adapted, it is the same to brew or decoct after image tea, safe, can several times of drinking at any time for a long time.
But there is no be suitble to heat symptom-complex so far（Body heat is irritated, appearance it is red it is red, lip is red and dry, the dry thirsty, cool drink of pharynx, big constipation
Knot, scanty drak urine and red tongue with yellowish fur etc.）It drinks, heat symptom-complex can be alleviated and can effectively treat urarthritis on behalf of the tea.
Invention content
The present invention be in order to solve the above-mentioned technical problem present in the prior art, provide it is a kind of treat heat symptom-complex gouty pass
Section is scorching on behalf of the tea.
Technical solution of the invention is：It is a kind of to treat heat symptom-complex urarthritis on behalf of the tea, each component mass ratio
It is as follows：2 parts of honeysuckle, 2 parts of Radix Angelicae Sinensis, 1 part of Radix Glycyrrhizae, 1 part of pueraria lobata, 1 part of purslane, 1 part of Semen Coicis, 1 part of hoveniae semoveniae semen, 1 part of Poria cocos.
The present invention overcomes traditional decoctions to decoct the shortcomings of cumbersome, inconvenient to carry, can several times of drinking at any time for a long time, slowly adjust
It controls, can not only alleviate heat symptom-complex but also can effectively treat urarthritis, and can avoid the recurrent exerbation of urarthritis.
Specific implementation mode
On behalf of the tea, each component mass ratio is as follows for the cold card urarthritis for the treatment of of the present invention：Honeysuckle 20g, Radix Angelicae Sinensis
20g, Radix Glycyrrhizae 10g, pueraria lobata 10g, purslane 10g, Semen Coicis 10g, hoveniae semoveniae semen 10g, Poria cocos 10g.By the above integration of drinking and medicinal herbs
It is crushed after mixing after Chinese medicine individually crushes, or mixing, tea bag then is made in gained crushed material packaging（5g/ packets or 10g/ packets）
, brew or taken after decocting.
Experiment：
Honeysuckle 20g, Radix Angelicae Sinensis 20g, Radix Glycyrrhizae 10g, pueraria lobata 10g, purslane 10g, Semen Coicis 10g, hoveniae semoveniae semen 10g and Poria cocos
10g is placed in round-bottomed flask, and 7 times of amount distilled waters, heating and refluxing extraction 2 times is added 2 hours every time, to merge extracting solution, steamed in rotation
Extracting solution is concentrated into 100ml by hair instrument（Extracting solution of the embodiment of the present invention）, amount to 10 parts.
Extracting honeysuckle, Radix Angelicae Sinensis, pueraria lobata, purslane, Semen Coicis, hoveniae semoveniae semen and each 100g of Poria cocos prepare folk prescription extracting solution respectively,
Extracting method is same as above, and per folk prescription extracting solution 100ml, amounts to 10 parts.
1. grouping
88 200 ± 20g SD rats adaptable feds 3 days, are randomly divided into 11 groups, blank group, model group, positive drug group, this
Inventive embodiments group, honeysuckle group, when grouping, pueraria lobata group, purslane group, Semen Coicis group, hoveniae semoveniae semen group and Poria cocos group, every group 8.
2. prepared by urarthritis model
The crystallization of 500mg Monosodium urates plus 2ml Tween 80s are taken, is settled to 20ml with physiological saline, 25mg/ml uric acid is made in heating stirring
Sodium solution.In addition to normal group, remaining group 10% chloraldurate of rat（0.3ml/100g）After intraperitoneal anesthesia, in right ankle joint
Interior injection uric acid sodium solution（25mg/ml）, capsular ligament offside of being subject to heaves, and establishes rat urarthritis model.
3. prepared by Heat Syndrome of TCM model
Urarthritis rat model established above is placed in low temperature（0±2℃）Environment is once a day, small one at a time
When, continue two weeks, causes cold card urarthritis rat model.
4. administration
Normal group and model group give the physiological saline of therapeutic dose after modeling；Positive drug group gives the autumn according to 1.5mg/kg
Tazettine is configured with physiological saline, and daily gastric infusion is primary；Group of the embodiment of the present invention gives extracting solution of the embodiment of the present invention,
Remaining each group gives folk prescription extracting solution respectively, and dosage is 1ml/100g；Each group successive administration 7 days.
5. detection method
Naked-eye observation each group mouse state and 0 after modeling, 24,48,72,96,120,144,8 time points such as 168h, with nothing
The perimeter value of elastic cotton thread and four use stainless steel band table calliper each group Rat Right metapedes ankle-joints, calculates and records ankle-joint
Perimeter increases percentage, calculation formula：Perimeter increase percentage=（Minute point joint Zhou Jing-initial Zhou Jing）/ initial Zhou Jing
×100%.In taking rat blood serum after the last administration, using enzyme-linked immunization to α-NAG, β-gal, SOD, UA, TNF-α in serum
Content is detected, and specific detecting step, method are operated by kit specification.
6. statistical method
All data are calculated using SPSS16.0 softwares, measurement data mean ± standard deviation（）It indicates, p≤
0.05 has statistical significance.
7. result
7.1 naked-eye observation results：After the administration of group of the embodiment of the present invention, rat restlessness, scanty drak urine, dry and hard excrement symptom are bright
Aobvious to mitigate, amount of drinking water obviously also significantly reduces.Illustrate, heat symptom-complex can be effectively relieved in the embodiment of the present invention.
7.2 ankle-joint perimeters increase percentage（%）Such as table 1-1, table 1-2, table 1-3, table 1-4.
Table 1-1
Table 1-2
Table 1-3
Table 1-4
a-p<0.01, b-p<0.05, compared with normal；c-p<0.01, compared with model, d-p<
0.05, compared with model；e-p<0.01, f-p<0.05, compared with colchicine.
Table 1-1, table 1-2, table 1-3, table 1-4 the result shows that：Each point in time, blank control group are significant with model group
Difference illustrates modeling success.When for 24 hours, positive drug group and the significant difference of model group illustrate that there is colchicin treatment to make
With.When 48h, embodiment（The embodiment of the present invention）There was no significant difference for group and the significant difference of model group and positive drug group.
When 72h, embodiment group does not have significant difference with the significant difference of model group and positive drug group.96h and after, embodiment
Group has the trend for alleviating urarthritis.Each point in time, when be grouped into it is not statistically significant with model group, with blank group,
Positive drug group is statistically significant, and Radix Angelicae Sinensis simple is prompted to use no effect；Poria cocos group, pueraria lobata group, honeysuckle group, purslane
Group, Semen Coicis group, hoveniae semoveniae semen group and model group are statistically significant, statistically significant with positive drug group, prompt Poria cocos, pueraria lobata,
Honeysuckle, purslane, Semen Coicis, hoveniae semoveniae semen simple are acted on little using energy slight relief urarthritis.
α-NAG, β-gal, SOD, UA, TNF-α content detection result such as table 2 in 7.3 serum.
Table 2
| Grouping | α-NGA(ng/L） | β-gal（pg/ml） | SOD(ng/L) | UA（μmol/L) | TNF-α（ng/L） |
| Blank group | 180.96±5.62ce | 85.66±4.39ce | 164.22±3.93ce | 238.89±6.83ce | 275.66±6.43ce |
| Model group | 218.40±9.42ae | 119.13±4.49ae | 111.5±6.68ae | 290.66±6.60ae | 302.91±5.67ae |
| Positive drug group | 188±3.93ac | 94.63±3.96ac | 158.63±4.37ac | 249±6.26ac | 281.13±3.44ac |
| Embodiment group | 181.75±4.33ce | 86.55±3.84ce | 163.60±4.10cf | 237.94±3.84ce | 274.88±4.39ce |
| Work as grouping | 217.76±9.76ae | 121.29±5.70ae | 112.08±7.40ae | 290.98±7.39ae | 302.79±707ae |
| Poria cocos group | 218.54±9.62ae | 120.41±4.50ae | 111.63±8.11ae | 290.48±6.49ae | 301.96±6.32ae |
| Pueraria lobata group | 202.54±5.48ace | 103.04±3.44ace | 134.45±3.92ace | 274.16±4.38ace | 292.66±5.33ace |
| Honeysuckle group | 218.42±10.56ae | 119.91±5.47ae | 112.04±5.38ae | 290.41±6.38ae | 302.89±6.31ae |
| Purslane group | 218.79±9.63ae | 120.91±4.79ae | 111.16±7.83ae | 290.06±7.27ae | 302.70±5.08ae |
| Semen Coicis group | 199.45±7.84ace | 102.04±5.74ace | 130.25±5.68ace | 270.41±6.44ace | 292.75±4.92ace |
| Hoveniae semoveniae semen group | 202.54±5.48ace | 103.04±3.44ace | 134.45±3.92ace | 274.16±4.38ace | 292.66±5.33ace |
a-p<0.01, b-p<0.05, compared with normal；c-p<0.01, d-p<0.05,
compared with model；e-p<0.01, f-p<0.05, compared with colchicine.
①：α-NAG blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can make
For the index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group and blank control group
There is no significant difference, illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group than significant difference, with
There was no significant difference for blank group and positive drug group, and it is horizontal to illustrate that the embodiment of the present invention can reduce α-NGA.
②：β-gal blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can make
For the index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group and blank control group
There is no significant difference, illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group than significant difference, with
There was no significant difference for blank group and positive drug group, and it is horizontal to illustrate that the embodiment of the present invention can reduce β-gal.
③：SOD blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can be used as
The index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group does not have with blank control group
Significant difference illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group are than significant difference, with sky
There was no significant difference with positive drug group for white group, illustrates the embodiment of the present invention] SOD levels can be increased.
④：UA blank control groups have significant difference with model group（p<0.05）, illustrate modeling success, and can be used as medicine
The index of object evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group does not have with blank control group
Significant difference illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group are than significant difference, with blank
There was no significant difference with positive drug group for group, illustrates that the embodiment of the present invention can reduce UA levels.
⑤：TNF-α blank control group has significant difference with model group（p<0.05）, illustrate modeling success, and can make
For the index of drug evaluation；Positive drug group and the significant difference (p of model group<0.01), positive drug group and blank control group
There is no significant difference, illustrates that colchicin has the therapeutic effect of GA；Embodiment group and model group than significant difference, with
There was no significant difference for blank group and positive drug group, illustrates that this hair inventive embodiments can reduce TNF-α level.
⑥：From the point of view of each index, not statistically significant with model group when being grouped into, with positive drug, blank group has statistics
Meaning prompts Radix Angelicae Sinensis simple to use invalid；Poria cocos group, pueraria lobata group, honeysuckle group, purslane group, Semen Coicis group, hoveniae semoveniae semen group with
Model group is statistically significant, statistically significant with positive drug group, prompts Poria cocos, pueraria lobata, honeysuckle, purslane, Semen Coicis, trifoliate orange
Dulcis simples are acted on little using energy slight relief urarthritis.
To sum up the result shows that：
The present invention can not only alleviate heat symptom-complex, and have the function for the treatment of urarthritis well, can improve gouty pass
Arthroncus caused by section is scorching, inflammatory factor change, Antioxidative Factors change etc..
Claims (1)
1. a kind for the treatment of heat symptom-complex urarthritis on behalf of the tea, it is characterised in that each component mass ratio is as follows：2 parts of honeysuckle,
2 parts of Radix Angelicae Sinensis, 1 part of Radix Glycyrrhizae, 1 part of pueraria lobata, 1 part of purslane, 1 part of Semen Coicis, 1 part of hoveniae semoveniae semen, 1 part of Poria cocos.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810431705.7A CN108310275A (en) | 2018-05-08 | 2018-05-08 | Treat heat symptom-complex urarthritis on behalf of the tea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810431705.7A CN108310275A (en) | 2018-05-08 | 2018-05-08 | Treat heat symptom-complex urarthritis on behalf of the tea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310275A true CN108310275A (en) | 2018-07-24 |
Family
ID=62895911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810431705.7A Pending CN108310275A (en) | 2018-05-08 | 2018-05-08 | Treat heat symptom-complex urarthritis on behalf of the tea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310275A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021223041A1 (en) * | 2020-05-07 | 2021-11-11 | 广州市比拓人力资源有限公司 | Tea which is capable of reducing uric acid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412612A (en) * | 2017-04-19 | 2017-12-01 | 广西大学 | A kind of health care anti-trioxypurine alternative tea and preparation method thereof |
-
2018
- 2018-05-08 CN CN201810431705.7A patent/CN108310275A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412612A (en) * | 2017-04-19 | 2017-12-01 | 广西大学 | A kind of health care anti-trioxypurine alternative tea and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王强虎著: "《名医世纪传媒 痛风防治20法》", 31 January 2018, 河南科学技术出版社 * |
| 顾硕等: "老年痛风72例临床分析", 《现代中西医结合杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021223041A1 (en) * | 2020-05-07 | 2021-11-11 | 广州市比拓人力资源有限公司 | Tea which is capable of reducing uric acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698210A (en) | Traditional Chinese medicine capable of invigorating spleen and supplementing qi and treating gastroptosis | |
| CN102018950B (en) | Drug for treating hypertension | |
| CN108310275A (en) | Treat heat symptom-complex urarthritis on behalf of the tea | |
| CN103330928B (en) | Traditional Chinese medicine composition used for treating gastric ulcer and preparation method thereof | |
| CN108324874A (en) | Treat syndrome of intermingled heat and cold urarthritis on behalf of the tea | |
| CN102886036B (en) | Traditional Chinese medicine for treating syndrome of congealing cold with blood stasis type dysmenorrheal disease | |
| CN105288462A (en) | Traditional Chinese medicine composition effective in gastric cancer treatment and preparation method of traditional Chinese medicine composition effective in gastric cancer treatment | |
| CN104189368A (en) | Traditional Chinese medicinal composition for treating spleen and stomach diseases and preparation method thereof | |
| CN104001131A (en) | Oral traditional Chinese medicine for preventing and treating stress ulcers | |
| CN104383244A (en) | Traditional Chinese medicine composition for treating esophagus cancer and preparation method of traditional Chinese medicine composition | |
| CN105267818B (en) | A kind of Chinese medicine composition and preparation method thereof for treating epigastric pain | |
| CN108355083A (en) | The cold card urarthritis for the treatment of is on behalf of the tea | |
| CN101129584A (en) | Chinese medicine preparation for treating post partum hypogalactia | |
| CN105288180A (en) | Traditional Chinese medicine composition for treating early and middle gastric cancer and preparation method of traditional Chinese medicine composition for treating early and middle gastric cancer | |
| CN104027447A (en) | Traditional Chinese medicine for treating cancer | |
| CN104547223A (en) | Traditional Chinese medicine for treating phlegm-blood stasis syndrome type non-alcoholic fatty liver disease | |
| CN106728640A (en) | It is a kind of to treat the Chinese medicine composition that irregular menstruation promotes pregnancy | |
| CN105641222A (en) | Traditional Chinese medicine for treating gastric cancer | |
| CN103638441A (en) | Traditional Chinese medicinal composition for treating fatty liver with liver stagnation and spleen deficiency symptom | |
| CN101979051A (en) | Traditional Chinese medicine for treating chronic gastritis | |
| CN102366474A (en) | Chinese herbal medicine for treating gingivitis | |
| CN102258624A (en) | Chinese medicinal composition for treating gastritis | |
| CN101028422A (en) | Chinese-medicinal decoction for treating hives | |
| CN105194332A (en) | Traditional Chinese medicine for treating non-alcoholic fatty liver disease | |
| CN106668702A (en) | Hui-nationality traditional Chinese medicine taxus chinensis bark oral solution for treating gastric cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180724 |
|
| RJ01 | Rejection of invention patent application after publication |